SCHEMBL13035810

SCHEMBL13035810

Cc1cccc(-c2c(C)n[nH]c2C)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT2 P31751 2/20 0.67
▸ CHEK1 O14757 1/20 0.67
▸ IKBKB O14920 3/20 0.49
▸ IKBKE Q14164 1/20 0.49
▸ NOTUM Q6P988 1/20 0.46
▸ IDO1 P14902 1/20 0.46
▸ METAP2 P50579 1/20 0.46
▸ ACVR1 Q04771 1/20 0.46
▸ KMT2A Q03164 1/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ NCOA2 Q15596 1/20 0.43
▸ NCOA1 Q15788 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20213984 0.82 AKT2 (0.62) AKT2CHEK1IKBKBIKBKENOTUM
SCHEMBL26832622 0.82 AKT2 (0.62) AKT2CHEK1IKBKBIKBKEIDO1
SCHEMBL30829475 0.82 AKT2 (0.62) AKT2CHEK1IKBKBIKBKENOTUM
SCHEMBL16115987 0.82 IKBKB (0.71) AKT2CHEK1IKBKBIKBKEIDO1
SCHEMBL873114 0.80 AKT2 (1.00) AKT2CHEK1IKBKBIKBKEACVR1
SCHEMBL8715209 0.80 CHEK1 (0.47) AKT2CHEK1IKBKBIKBKENOTUM
SCHEMBL24765276 0.80 CHEK1 (0.59) AKT2CHEK1IKBKENOTUMLMNA
SCHEMBL24732319 0.80 CHEK1 (0.59) AKT2CHEK1IKBKBIKBKEACVR1
SCHEMBL26834432 0.80 AKT2 (0.59) AKT2CHEK1IKBKBIKBKEACVR1
SCHEMBL15653783 0.78 AKT2 (0.57) AKT2CHEK1IKBKBIKBKEACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 — — US disclosed
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 — — US disclosed
US-20130203747-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION GILEAD SCIENCES, INC. (US) 2013-08-08 — — US disclosed
US-8338441-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2012-12-25 — — US disclosed
US-8338441-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2012-12-25 — — US disclosed
WO-2010130034-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — WO disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — US disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 AKT2 1545/4885CHEK1 549/4885IKBKB 648/4885
US-20130203747-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 AKT2 1545/4885CHEK1 549/4885IKBKB 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback